



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|-------------------------------------|
| SDS Title: Neostigmine Methylsulfate Injection, USP Safety Data Sheet | SDS Number: SDS-000035 | Page Number: Page 1 of 16 |
| Function: Regulatory Affairs | Effective Date: July 25, 2024 | Version number: 3.0 |

Section 1. Identification

GHS product identifier : Neostigmine Methylsulfate Injection, USP

Other means of identification : Not available.

Product type : Liquid.

Relevant identified uses of the substance or mixture and uses advised against

Product use : Pharmaceuticals. (For intended use only.)
Observe technical data sheet/instructions for use.
Specific Treatments: cholinesterase inhibition

Area of application : Professional applications.

Supplier's details : Meitheal Pharmaceuticals, Inc.
8700 W. Bryn Mawr, Suite 600S
Chicago, IL 60631

Telephone: 224-443-4617
www.meithealpharma.com

e-mail address of person responsible for this SDS : info@meithealpharma.com

Emergency telephone number (with hours of operation) : 844-824-8426 (Monday - Friday, 08:00 - 18:00 CST)

Section 2. Hazards identification

OSHA/HCS status : While this material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200), this SDS contains valuable information critical to the safe handling and proper use of the product. This SDS should be retained and available for employees and other users of this product.

Classification of the substance or mixture : Not classified.

GHS label elements

Signal word : No signal word.

Hazard statements : No known significant effects or critical hazards.

Precautionary statements

Prevention : Not applicable.

Response : Not applicable.

Storage : Not applicable.

Disposal : Not applicable.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|-------------------------------------|
| SDS Title: Neostigmine Methylsulfate Injection, USP Safety Data Sheet | SDS Number: SDS-000035 | Page Number: Page 2 of 16 |
| Function: Regulatory Affairs | Effective Date: July 25, 2024 | Version number: 3.0 |

Section 2. Hazards identification

Hazards not otherwise classified : None known.

Section 3. Composition/information on ingredients

Substance/mixture : Mixture
Other means of identification : Not available.

| Ingredient name | Other names | % | Identifiers |
|---|----------------------------|------|----------------|
| water | - | ≥90 | CAS: 7732-18-5 |
| phenol | - | <1 | CAS: 108-95-2 |
| acetic acid | Acetic acid | ≤0.3 | CAS: 64-19-7 |
| sodium hydroxide | - | ≤0.3 | CAS: 1310-73-2 |
| nitrogen | Nitrogen | ≤0.3 | CAS: 7727-37-9 |
| neostigmine metilsulfate | Neostigmine methylsulfate | ≤0.1 | CAS: 51-60-5 |
| Acetic acid, sodium salt, hydrate (1:1:3) | Sodium acetate, trihydrate | ≤0.1 | CAS: 6131-90-4 |

Any concentration shown as a range is to protect confidentiality or is due to batch variation.

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified and hence require reporting in this section.

Section 4. First aid measures

Description of necessary first aid measures

- Eye contact** : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
- Inhalation** : Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.
- Skin contact** : Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
- Ingestion** : Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

Most important symptoms/effects, acute and delayed

Potential acute health effects

- Eye contact** : No known significant effects or critical hazards.
- Inhalation** : No known significant effects or critical hazards.
- Skin contact** : No known significant effects or critical hazards.
- Ingestion** : No known significant effects or critical hazards.

Over-exposure signs/symptoms



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|-------------------------------------|
| SDS Title: Neostigmine Methylsulfate Injection, USP Safety Data Sheet | SDS Number: SDS-000035 | Page Number: Page 3 of 16 |
| Function: Regulatory Affairs | Effective Date: July 25, 2024 | Version number: 3.0 |

Section 4. First aid measures

- Eye contact** : No specific data.
- Inhalation** : No specific data.
- Skin contact** : No specific data.
- Ingestion** : No specific data.

Indication of immediate medical attention and special treatment needed, if necessary

- Notes to physician** : Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
- Specific treatments** : No specific treatment.
- Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training.

See toxicological information (Section 11)

Section 5. Fire-fighting measures

Extinguishing media

- Suitable extinguishing media** : Use an extinguishing agent suitable for the surrounding fire.
- Unsuitable extinguishing media** : Do not use water jet.

Specific hazards arising from the chemical

- : In a fire or if heated, a pressure increase will occur and the container may burst.
- Hazardous thermal decomposition products** : Decomposition products may include the following materials:
carbon dioxide
carbon monoxide

Special protective actions for fire-fighters

- : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
- Special protective equipment for fire-fighters** : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Section 6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

- For non-emergency personnel** : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.
- For emergency responders** : If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|-------------------------------------|
| SDS Title: Neostigmine Methylsulfate Injection, USP Safety Data Sheet | SDS Number: SDS-000035 | Page Number: Page 4 of 16 |
| Function: Regulatory Affairs | Effective Date: July 25, 2024 | Version number: 3.0 |

Section 6. Accidental release measures

Environmental precautions : Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

Methods and materials for containment and cleaning up

Small spill : Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

Large spill : Stop leak if without risk. Move containers from spill area. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Dispose of via a licensed waste disposal contractor. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations.

Section 7. Handling and storage

Precautions for safe handling

Protective measures : Put on appropriate personal protective equipment (see Section 8).

Advice on general occupational hygiene : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

Conditions for safe storage, including any incompatibilities : Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Section 8. Exposure controls/personal protection

Control parameters

Occupational exposure limits

| Ingredient name | Exposure limits |
|------------------------|--|
| water phenol | None. ACGIH TLV (United States, 1/2024) A4. Absorbed through skin. TWA 8 hours: 5 ppm. TWA 8 hours: 19 mg/m ³ . NIOSH REL (United States, 10/2020) Absorbed through skin. TWA 10 hours: 5 ppm. |



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|-------------------------------------|
| SDS Title: Neostigmine Methylsulfate Injection, USP Safety Data Sheet | SDS Number: SDS-000035 | Page Number: Page 5 of 16 |
| Function: Regulatory Affairs | Effective Date: July 25, 2024 | Version number: 3.0 |

Section 8. Exposure controls/personal protection

| | |
|---|--|
| acetic acid | <p>TWA 10 hours: 19 mg/m³. CEIL 15 minutes: 15.6 ppm. CEIL 15 minutes: 60 mg/m³. OSHA PEL (United States, 5/2018) Absorbed through skin. TWA 8 hours: 5 ppm. TWA 8 hours: 19 mg/m³. CAL OSHA PEL (United States, 5/2018) Absorbed through skin. TWA 8 hours: 19 mg/m³. TWA 8 hours: 5 ppm. ACGIH TLV (United States, 1/2024) TWA 8 hours: 10 ppm. TWA 8 hours: 25 mg/m³. STEL 15 minutes: 15 ppm. STEL 15 minutes: 37 mg/m³. NIOSH REL (United States, 10/2020) TWA 10 hours: 10 ppm. TWA 10 hours: 25 mg/m³. STEL 15 minutes: 15 ppm. STEL 15 minutes: 37 mg/m³. OSHA PEL (United States, 5/2018) TWA 8 hours: 10 ppm. TWA 8 hours: 25 mg/m³. CAL OSHA PEL (United States, 5/2018) STEL 15 minutes: 37 mg/m³. STEL 15 minutes: 15 ppm. C: 40 ppm. TWA 8 hours: 25 mg/m³. TWA 8 hours: 10 ppm.</p> |
| sodium hydroxide | <p>ACGIH TLV (United States, 1/2024) C: 2 mg/m³. NIOSH REL (United States, 10/2020) CEIL: 2 mg/m³. OSHA PEL (United States, 5/2018) TWA 8 hours: 2 mg/m³. CAL OSHA PEL (United States, 5/2018) C: 2 mg/m³.</p> |
| nitrogen | <p>ACGIH TLV (United States, 1/2024) Oxygen depletion [asphyxiant].</p> |
| neostigmine metilsulfate | <p>None.</p> |
| Acetic acid, sodium salt, hydrate (1:1:3) | <p>None.</p> |

Effective

Appropriate engineering controls

: Good general ventilation should be sufficient to control worker exposure to airborne contaminants.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|-------------------------------------|
| SDS Title: Neostigmine Methylsulfate Injection, USP Safety Data Sheet | SDS Number: SDS-000035 | Page Number: Page 6 of 16 |
| Function: Regulatory Affairs | Effective Date: July 25, 2024 | Version number: 3.0 |

Section 8. Exposure controls/personal protection

- Environmental exposure controls** : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.
- Individual protection measures**
 - Hygiene measures** : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
 - Eye/face protection** : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.
 - Skin protection**
 - Hand protection** : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.
 - Body protection** : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
 - Other skin protection** : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
 - Respiratory protection** : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Section 9. Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

- Appearance**
 - Physical state** : Liquid. [Clear.]
 - Color** : Colorless.
- Odor** : Not available.
- Odor threshold** : Not available.
- pH** : 5 to 6.5
- Melting point** : Not available.
- Boiling point or initial boiling point and boiling range** : Not available.
- Flash point** : Not available.

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|-------------------------------------|
| SDS Title: Neostigmine Methylsulfate Injection, USP Safety Data Sheet | SDS Number: SDS-000035 | Page Number: Page 7 of 16 |
| Function: Regulatory Affairs | Effective Date: July 25, 2024 | Version number: 3.0 |

Section 9. Physical and chemical properties

Evaporation rate : Not available.

Flammability : Not available.

Lower and upper explosion limit/flammability limit : Not available.

Vapor pressure :

| Ingredient name | Vapor Pressure at 20°C | | | Vapor pressure at 50°C | | |
|-----------------|------------------------|-----|--------|------------------------|------|--------|
| | mm Hg | kPa | Method | mm Hg | kPa | Method |
| water | 17.5 | 2.3 | | 92.258 | 12.3 | |

Relative vapor density : Not available.

Relative density : 1 [Water = 1]

Density : 0.9971 to 0.9986 g/cm³

Solubility(ies) : Not available.

Partition coefficient: n-octanol/water : Not applicable.

Auto-ignition temperature : Not available.

Decomposition temperature : Not available.

SADT : Not available.

Viscosity : Dynamic (room temperature): Not available.
Kinematic (room temperature): Not available.
Kinematic (40°C (104°F)): Not available.

Flow time (ISO 2431) : Not available.

Particle characteristics

Median particle size : Not applicable.

Other information

Physical/chemical properties comments : No additional information.

Section 10. Stability and reactivity

Reactivity : No specific test data related to reactivity available for this product or its ingredients.

Chemical stability : The product is stable.

Possibility of hazardous reactions : Under normal conditions of storage and use, hazardous reactions will not occur.
Under normal conditions of storage and use, hazardous polymerization will not occur.

Conditions to avoid : No specific data.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|-------------------------------------|
| SDS Title: Neostigmine Methylsulfate Injection, USP Safety Data Sheet | SDS Number: SDS-000035 | Page Number: Page 8 of 16 |
| Function: Regulatory Affairs | Effective Date: July 25, 2024 | Version number: 3.0 |

Section 10. Stability and reactivity

Incompatible materials : Reactive or incompatible with the following materials: oxidizing materials.

Hazardous decomposition products : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Section 11. Toxicological information

Information on toxicological effects

Acute toxicity

| Product/ingredient name | Result | Species | Dose | Exposure |
|-------------------------|---------------------------------|---------|-------------------------|----------|
| phenol | LC50 Inhalation Dusts and mists | Rat | 316 mg/m ³ | 4 hours |
| | LD50 Dermal | Rabbit | 630 mg/kg | - |
| | LD50 Dermal | Rat | 669 mg/kg | - |
| | LD50 Oral | Rat | 317 mg/kg | - |
| acetic acid | LC50 Inhalation Vapor | Rat | 11000 mg/m ³ | 4 hours |
| | LD50 Dermal | Rabbit | 1060 mg/kg | - |
| | LD50 Oral | Rat | 3310 mg/kg | - |

Irritation/Corrosion

| Product/ingredient name | Result | Species | Score | Exposure | Observation |
|-------------------------|------------------------|---------|-------|------------------|-------------|
| phenol | Eyes - Mild irritant | Rabbit | - | 0.5 minutes 5 mg | - |
| | Eyes - Severe irritant | Rabbit | - | 5 mg | - |
| | Skin - Mild irritant | Rabbit | - | 100 mg | - |
| acetic acid | Skin - Severe irritant | Rabbit | - | 535 mg | - |
| | Eyes - Mild irritant | Rabbit | - | 0.5 minutes 5 mg | - |
| | Skin - Mild irritant | Rabbit | - | 24 hours 50 mg | - |
| sodium hydroxide | Skin - Severe irritant | Rabbit | - | 525 mg | - |
| | Eyes - Mild irritant | Rabbit | - | 400 ug | - |
| | Eyes - Severe irritant | Rabbit | - | 1 % | - |
| | Eyes - Severe irritant | Rabbit | - | 0.5 minutes 1 mg | - |
| | Eyes - Severe irritant | Rabbit | - | 24 hours 50 ug | - |
| | Skin - Severe irritant | Rabbit | - | 24 hours 500 mg | - |

Sensitization

Not available.

Mutagenicity

Conclusion/Summary : Not available.

Carcinogenicity



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|-------------------------------------|
| SDS Title: Neostigmine Methylsulfate Injection, USP Safety Data Sheet | SDS Number: SDS-000035 | Page Number: Page 9 of 16 |
| Function: Regulatory Affairs | Effective Date: July 25, 2024 | Version number: 3.0 |

Section 11. Toxicological information

Conclusion/Summary : Not available.

Classification

| Product/ingredient name | OSHA | IARC | NTP |
|-------------------------|------|------|-----|
| phenol | - | 3 | - |

Reproductive toxicity

Conclusion/Summary : Not available.

Teratogenicity

Conclusion/Summary : Not available.

Specific target organ toxicity (single exposure)

| Name | Category | Route of exposure | Target organs |
|----------------------------|--------------------------|-------------------|-----------------------------------|
| phenol sodium hydroxide | Category 1 Category 3 | - - | - Respiratory tract irritation |

Specific target organ toxicity (repeated exposure)

| Name | Category | Route of exposure | Target organs |
|--------|------------|-------------------|-----------------------------------|
| phenol | Category 2 | - | kidneys, liver, nervous system |

Aspiration hazard

Not available.

Information on the likely routes of exposure : Not available.

Potential acute health effects

- Eye contact** : No known significant effects or critical hazards.
- Inhalation** : No known significant effects or critical hazards.
- Skin contact** : No known significant effects or critical hazards.
- Ingestion** : No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

- Eye contact** : No specific data.
- Inhalation** : No specific data.
- Skin contact** : No specific data.
- Ingestion** : No specific data.

Delayed and immediate effects and also chronic effects from short and long term exposure

Short term exposure

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|--------------------------------------|
| SDS Title: Neostigmine Methylsulfate Injection, USP Safety Data Sheet | SDS Number: SDS-000035 | Page Number: Page 10 of 16 |
| Function: Regulatory Affairs | Effective Date: July 25, 2024 | Version number: 3.0 |

Section 11. Toxicological information

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Long term exposure

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Potential chronic health effects

General : No known significant effects or critical hazards.

Carcinogenicity : No known significant effects or critical hazards.

Mutagenicity : No known significant effects or critical hazards.

Reproductive toxicity : No known significant effects or critical hazards.

Numerical measures of toxicity

Acute toxicity estimates

| Product/ingredient name | Oral (mg/kg) | Dermal (mg/kg) | Inhalation (gases) (ppm) | Inhalation (vapors) (mg/l) | Inhalation (dusts and mists) (mg/l) |
|--------------------------|--------------|----------------|--------------------------|----------------------------|-------------------------------------|
| phenol | 317 | 630 | N/A | N/A | 0.316 |
| acetic acid | 3310 | 1060 | N/A | 11 | N/A |
| neostigmine metilsulfate | 100 | 5 | N/A | 0.05 | N/A |

Section 12. Ecological information

Toxicity

| Product/ingredient name | Result | Species | Exposure |
|-------------------------|-----------------------------------|---|----------|
| phenol | Acute EC50 36 mg/l Marine water | Algae - <i>Hormosira banksii</i> - Gamete | 72 hours |
| | Acute EC50 10 ppm Marine water | Algae - <i>Macrocystis pyrifera</i> - Young | 4 days |
| | Acute EC50 94 mg/l Fresh water | Aquatic plants - <i>Lemna aequinoctialis</i> | 96 hours |
| | Acute EC50 4200 µg/l Fresh water | Daphnia - <i>Daphnia magna</i> | 48 hours |
| | Acute LC50 800 µg/l Marine water | Crustaceans - <i>Archaeomysis kokuboi</i> - Juvenile (Fledgling, Hatchling, Weanling) | 48 hours |
| | Acute LC50 1555 µg/l Fresh water | Fish - <i>Cirrhinus mrigala</i> - Larvae | 96 hours |
| | Chronic NOEC 16 µg/l Marine water | Algae - <i>Hormosira banksii</i> - Gamete | 72 hours |
| | Chronic NOEC 1.5 mg/l Fresh water | Daphnia - <i>Daphnia magna</i> | 21 days |



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|--------------------------------------|
| SDS Title: Neostigmine Methylsulfate Injection, USP Safety Data Sheet | SDS Number: SDS-000035 | Page Number: Page 11 of 16 |
| Function: Regulatory Affairs | Effective Date: July 25, 2024 | Version number: 3.0 |

Section 12. Ecological information

| | | | |
|------------------|---|---|--|
| acetic acid | Chronic NOEC 118 µg/l Fresh water Acute EC50 73400 µg/l Fresh water Acute EC50 65000 µg/l Fresh water | Fish - <i>Oncorhynchus mykiss</i> Algae - <i>Navicula seminulum</i> Daphnia - <i>Daphnia magna</i> - Neonate | 90 days 96 hours 48 hours |
| sodium hydroxide | Acute LC50 32 mg/l Marine water Acute LC50 75000 µg/l Fresh water Acute EC50 40.38 mg/l Fresh water Acute LC50 125 ppm Fresh water | Crustaceans - <i>Artemia salina</i> Fish - <i>Lepomis macrochirus</i> Crustaceans - <i>Ceriodaphnia dubia</i> - Neonate Fish - <i>Gambusia affinis</i> - Adult | 48 hours 96 hours 48 hours 96 hours |

Conclusion/Summary : Not available.

Persistence and degradability

| Product/ingredient name | Test | Result | Dose | Inoculum |
|-------------------------|---|-------------------------------|------|----------|
| phenol | OECD 301C Ready Biodegradability - Modified MITI Test (I) | 62 % - Readily - 4.16667 days | - | - |

| Product/ingredient name | Aquatic half-life | Photolysis | Biodegradability |
|-------------------------|-------------------|------------|------------------|
| phenol | - | - | Readily |
| acetic acid | - | - | Readily |

Bioaccumulative potential

| Product/ingredient name | LogP _{ow} | BCF | Potential |
|---|--------------------|------|-----------|
| water | -1.38 | - | Low |
| phenol | 1.47 | 647 | High |
| acetic acid | -0.17 | 3.16 | Low |
| nitrogen | 0.67 | - | Low |
| Acetic acid, sodium salt, hydrate (1:1:3) | -4.22 | - | Low |

Mobility in soil

Soil/water partition coefficient (K_{oc}) : Not available.

Other adverse effects : No known significant effects or critical hazards.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|--------------------------------------|
| SDS Title: Neostigmine Methylsulfate Injection, USP Safety Data Sheet | SDS Number: SDS-000035 | Page Number: Page 12 of 16 |
| Function: Regulatory Affairs | Effective Date: July 25, 2024 | Version number: 3.0 |

Section 13. Disposal considerations

Disposal methods : The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

Section 14. Transport information

| | DOT Classification | IMDG | IATA |
|-----------------------------------|--------------------|----------------|----------------|
| UN number | Not regulated. | Not regulated. | Not regulated. |
| UN proper shipping name | - | - | - |
| Transport hazard class(es) | - | - | - |
| Packing group | - | - | - |
| Environmental hazards | No. | No. | No. |

Additional information

Special precautions for user : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

Transport in bulk according to IMO instruments : Not available.

Section 15. Regulatory information

U.S. Federal regulations : **TSCA 8(a) CDR Exempt/Partial exemption:** Not determined
United States inventory (TSCA 8b): Not determined.
Clean Water Act (CWA) 307: phenol
Clean Water Act (CWA) 311: phenol; acetic acid; sodium hydroxide



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|--------------------------------------|
| SDS Title: Neostigmine Methylsulfate Injection, USP Safety Data Sheet | SDS Number: SDS-000035 | Page Number: Page 13 of 16 |
| Function: Regulatory Affairs | Effective Date: July 25, 2024 | Version number: 3.0 |

Section 15. Regulatory information

Clean Air Act Section 112 : Listed

(b) Hazardous Air Pollutants (HAPs)

Clean Air Act Section 602 Class I Substances : Not listed

Clean Air Act Section 602 Class II Substances : Not listed

DEA List I Chemicals (Precursor Chemicals) : Not listed

DEA List II Chemicals (Essential Chemicals) : Not listed

SARA 302/304

Composition/information on ingredients

| Name | % | EHS | SARA 302 TPQ | | SARA 304 RQ | |
|--------|----|------|--------------|-----------|-------------|-----------|
| | | | (lbs) | (gallons) | (lbs) | (gallons) |
| phenol | <1 | Yes. | 500 / 10000 | - | 1000 | - |

SARA 304 RQ : 222222.2 lbs / 100888.9 kg [26709.5 gal / 101106.3 L]

SARA 311/312

Classification : Not applicable.

Composition/information on ingredients

| Name | % | Classification |
|------------------|------|--|
| phenol | <1 | ACUTE TOXICITY (oral) - Category 4 ACUTE TOXICITY (dermal) - Category 3 ACUTE TOXICITY (inhalation) - Category 2 SKIN CORROSION - Category 1B SERIOUS EYE DAMAGE - Category 1 GERM CELL MUTAGENICITY - Category 2 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) - Category 1 SPECIFIC TARGET ORGAN TOXICITY (REPEATED EXPOSURE) - Category 2 HNOC - Corrosive to digestive tract HNOC - Corrosive to respiratory tract |
| acetic acid | ≤0.3 | FLAMMABLE LIQUIDS - Category 3 ACUTE TOXICITY (dermal) - Category 4 ACUTE TOXICITY (inhalation) - Category 4 SKIN CORROSION - Category 1A SERIOUS EYE DAMAGE - Category 1 HNOC - Corrosive to digestive tract [severe] HNOC - Corrosive to respiratory tract [severe] |
| sodium hydroxide | ≤0.3 | CORROSIVE TO METALS - Category 1 SKIN CORROSION - Category 1A |



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|--------------------------------------|
| SDS Title: Neostigmine Methylsulfate Injection, USP Safety Data Sheet | SDS Number: SDS-000035 | Page Number: Page 14 of 16 |
| Function: Regulatory Affairs | Effective Date: July 25, 2024 | Version number: 3.0 |

Section 15. Regulatory information

| | | |
|--|------|--|
| nitrogen | ≤0.3 | SERIOUS EYE DAMAGE - Category 1 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3 HNOC - Corrosive to digestive tract [severe] |
| neostigmine metilsulfate | ≤0.1 | GASES UNDER PRESSURE - Compressed gas SIMPLE ASPHYXIANTS |
| Acetic acid, sodium salt, hydrate (1:1:3) | ≤0.1 | ACUTE TOXICITY (oral) - Category 3 ACUTE TOXICITY (dermal) - Category 1 ACUTE TOXICITY (inhalation) - Category 1 COMBUSTIBLE DUSTS |

SARA 313

Not applicable.

State regulations

- Massachusetts** : None of the components are listed.
- New York** : None of the components are listed.
- New Jersey** : The following components are listed: PHENOL
- Pennsylvania** : None of the components are listed.

California Prop. 65

This product does not require a Safe Harbor warning under California Prop. 65.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|--------------------------------------|
| SDS Title: Neostigmine Methylsulfate Injection, USP Safety Data Sheet | SDS Number: SDS-000035 | Page Number: Page 15 of 16 |
| Function: Regulatory Affairs | Effective Date: July 25, 2024 | Version number: 3.0 |

Section 16. Other information

Hazardous Material Information System (U.S.A.)

| | | |
|------------------|---|---|
| Health | / | 0 |
| Flammability | | 0 |
| Physical hazards | | 0 |

Caution: HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. Although HMIS® ratings and the associated label are not required on SDSs or products leaving a facility under 29 CFR 1910.1200, the preparer may choose to provide them. HMIS® ratings are to be used with a fully implemented HMIS® program. HMIS® is a registered trademark and service mark of the American Coatings Association, Inc.

The customer is responsible for determining the PPE code for this material. For more information on HMIS® Personal Protective Equipment (PPE) codes, consult the HMIS® Implementation Manual.

National Fire Protection Association (U.S.A.)



Procedure used to derive the classification

| Classification | Justification |
|-----------------|---------------|
| Not classified. | |

History

- Date of issue/Date of revision** : 07/25/2024
- Date of previous issue** : 08/03/2022
- Version** : 3.0
- Prepared by** : Sphera Solutions
- Key to abbreviations** :
 - ATE = Acute Toxicity Estimate
 - AMP = Acceptable maximum peak above the acceptable ceiling concentration for an 8-hr shift
 - BCF = Bioconcentration Factor
 - GHS = Globally Harmonized System of Classification and Labelling of Chemicals
 - IATA = International Air Transport Association
 - IBC = Intermediate Bulk Container
 - IMDG = International Maritime Dangerous Goods
 - LogPow = logarithm of the octanol/water partition coefficient
 - MARPOL = International Convention for the Prevention of Pollution From Ships, 1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution)
 - N/A = Not available
 - UN = United Nations

- References** :
 - HCS (U.S.A.)- Hazard Communication Standard
 - International transport regulations



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|--------------------------------------|
| SDS Title: Neostigmine Methylsulfate Injection, USP Safety Data Sheet | SDS Number: SDS-000035 | Page Number: Page 16 of 16 |
| Function: Regulatory Affairs | Effective Date: July 25, 2024 | Version number: 3.0 |

Section 16. Other information

✔ Indicates information that has changed from previously issued version.

[Notice to reader](#)

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.

Effective